Among IL17i-treated patients, those with PsA showed a 26% lower mortality risk (HR 0.74, 95% CI 0.61 to 0.89) compared with untreated patients, while in axSpA the magnitude of the effect was similar but did not reach statistical significance ( online supplemental table S6 and figure 3 ).
← all excerpts
Mortality incidence in spondyloarthritis: real-world evidence using the TriNetX Global Collaborative Network.
1
—
—